| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Tenaya Therapeutics, Inc.'s insiders have reduced their positions by a net 29,656 shares worth roughly $21K.
TNYA sits in the Biotechnology industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 539.8K | - | - | |
| Other | 263.1K | - | - | |
| VP | 118.3K | $93.8K | - | |
| 10% | 0 | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 21, 2022 | Goeddel David V71 | Director, 10% Owner | Buy | 9,615,384 | $2.60 | $24,999,998.40 | New | +36.9% | -22.3% | |
| Nov 21, 2022 | Srivastava Deepak | Director | Buy | 230,769 | $2.60 | $599,999.40 | +162.9% | +36.9% | -22.3% | |
| Nov 21, 2022 | Column Group III Gp, LP74 | 10% Owner | Buy | 9,615,384 | $2.60 | $24,999,998.40 | New | +36.9% | -22.3% | |
| Nov 17, 2022 | Casdin Eli50 | Director | Buy | 2,492,042 | $2.60 | $6,479,309.20 | +69.5% | +22.4% | -24.8% | |
| Apr 26, 2022 | Hoey Timothy82 | Chief Scientific Officer | Sell | 1,353 | $10.13 | $13,705.89 | -0.7% | -48.1% | -50.3% | |
| Aug 3, 2021 | Casdin Partners Master Fund, L.P.51 | 10% Owner | Buy | 850,000 | $15.00 | $12,750,000.00 | +35.8% | +36.8% | -72.3% | |
| Aug 3, 2021 | Casdin Eli50 | Director, 10% Owner | Buy | 850,000 | $15.00 | $12,750,000.00 | +35.8% | +36.8% | -72.3% |